Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice.
We investigated the synergetic effects of glucocorticoid and histamine H1 receptor antagonists on an atopic dermatitis model. Hairless mice were used in this study and an atopic dermatitis model was made by repeated application of 2,4,6-trinitrochlorobenzene. The effects of glucocorticoid, histamine H1 receptor antagonists, and the simultaneous use of these drugs were investigated by measuring scratching behavior, skin symptoms and nerve growth factor (NGF) in the skin. Topical application of prednisolone significantly inhibited scratching behavior, skin symptoms and NGF contents in the skin by repeated application. Olopatadine also showed a significant effect on scratching behavior and NGF contents in the skin, whereas chlorpheniramine showed no significant inhibitory effect on these indices. Furthermore, the combined use of prednisolone and olopatadine potentiated the inhibition of scratching behavior, skin symptoms, and NGF in the skin. From these findings, olopatadine potentiated the inhibitory effect of prednisolone on the symptoms of atopic dermatitis by inhibiting NGF.
Kagawa
Yoto
Y
Department of Medicinal Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Izawa
Kana
K
Yano
Haruna
H
Kamei
Chiaki
C
D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D000982:Antipruritics / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D003990:Dibenzoxepins / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008812:Mice, Hairless; D020932:Nerve Growth Factor / Q000378:metabolism; D000069605:Olopatadine Hydrochloride; D010853:Picryl Chloride / Q000008:administration & dosage / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy / Q000276:immunology; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013997:Time Factors
D000485:Allergens; D000982:Antipruritics; D003990:Dibenzoxepins; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D000069605:Olopatadine Hydrochloride; D020932:Nerve Growth Factor; D011239:Prednisolone; D010853:Picryl Chloride